Insider transaction details
Marcia Belvin, who serves as Senior Vice President and Chief Scientific Officer of CytomX Therapeutics, Inc. (NASDAQ: CTMX), sold 31,492 shares of the company's common stock on March 17, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at $6.423 each for a total of $202,273. The filing states the sale was made to cover tax obligations tied to the vesting of restricted stock units.
After the sale, Belvin's direct holdings in CytomX stood at 300,760 shares, which include 135,833 restricted stock units. The executed sale price was notably above the company's then-current market price of $4.78, which had declined nearly 2% over the prior week.
Share performance and valuation note
Over the past year, CTMX has recorded a dramatic rise, delivering a 613% return. At the same time, available valuation commentary in the market indicates the stock may be slightly overvalued at current trading levels.
Financing and clinical developments
CytomX has also launched a $250 million public offering of common stock and pre-funded warrants, with the shares in that offering priced at $5.30 apiece. The company has stated the proceeds are intended to support its drug development programs.
Analyst coverage has shifted following updated clinical data. Jefferies raised its price target on CytomX to $16.00 from $8.00 and maintained a Buy rating, citing meaningful de-risking after expanded Phase 1a data for the company's EpCAM antibody-drug conjugate. Oppenheimer increased its price target to $12.00 from $10.00 and kept an Outperform rating, citing promising trial results for the CX-2051 candidate.
The updated data for CX-2051 showed a 32% overall response rate at a 10 mg/kg dose and a median progression-free survival of 7.1 months. During CytomX's fourth-quarter 2025 earnings call, management highlighted clinical progress for its lead candidate, Varseta-M, though the company did not disclose specific financial metrics on that call.
Context and concluding observations
The insider sale, executed for tax purposes as restricted stock units vested, occurred in the context of strong year-over-year stock appreciation, an active financing effort, and recent analyst optimism tied to clinical readouts. The company continues to emphasize advancement of its clinical pipeline while pursuing market funding to support those programs.
Note - The article reports the transaction details, financing plans, analyst actions, and trial outcomes as disclosed in regulatory filings and company and analyst communications; it does not add additional information beyond those disclosures.